Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Recurrent/Metastatic ACC and PTC
NCT07521670Phase 2Not yet recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in adenoid cystic carcinoma (ACC), Papillary Thyroid Carcinoma (PTC), sponsored by National Cancer Centre Singapore. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
adenoid cystic carcinoma (ACC)Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT07521670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521670.